All In Biotech

Drug Trial Radar · NCT07188896

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Nov 30, 2029

Study completion Nov 30, 2030

Sponsor

Lead sponsor
Brian RiniAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals; Vanderbilt-Ingram Cancer Center
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.

Conditions

  • Advanced Renal Cell Carcinoma (aRCC)
  • Metastatic Renal Cell Carcinoma ( mRCC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

  • FianlimabDrug

    Fianlimab will be co-administered by IV.

  • IpilimumabDrug

    Ipilimumab will be administered by IV.

  • NivolumabDrug

    Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.

  • CemiplimabDrug

    Cemiplimab will co-administered by IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Penn State Cancer Institute

    Hershey, Pennsylvania · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.